A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).Bilal A. Siddiqui, Elizabeth Miller, Mark N. Stein et al.|Journal of Clinical Oncology|2025Cited by 4